Perspectives Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
نویسندگان
چکیده
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Peter Dreger, Johannes Schetelig, Niels Andersen, Paolo Corradini, Michel van Gelder, John Gribben, Eva Kimby, Mauricette Michallet, Carol Moreno, Stephan Stilgenbauer, and Emili Montserrat, on behalf of the European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT)
منابع مشابه
Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [<24 months] to chemoimmunotherapy, and/or presence of del[17p]/TP53 mutations). Currently, treatment algorithms for HR-CLL are being challenged by the introduction of novel cla...
متن کاملHematopoietic stem cell transplant therapy, clinical trials, complications, and quality of life for patients with Sickle cell anemia: Clinical potential and future perspectives
Background: Sickle cell anemia (SCA) is an inherited monogenic disorder. The clinical symptoms of SCA are protean, including vaso-occlusion, hemolysis, early stroke, leg ulcers, multi-organ failure, and increased risk of premature death. Hematopoietic stem cell transplantation is the only treatment identified to reduce SCA-related organ damage. Unfortunately, graft rejection is a significant im...
متن کاملNew insights into hematopoietic stem cell transplantation for chronic lymphocytic leukemia: a 2015 perspective.
A considerable body of evidence demonstrates that allogeneic hematopoietic stem cell transplantation (HSCT) offers the only potentially curative treatment option for patients with chronic lymphocytic leukemia (CLL). However, this approach is suitable for only a minority of CLL patients, owing to its significant treatment-related mortality and morbidity. Until recently, internationally accepted ...
متن کاملReview Series CHRONIC LYMPHOCYTIC LEUKEMIA: TAKING A BIG LEAP FORWARD A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs
Allogeneic stem cell transplantation (SCT) is considered potentially curative for some patientswith chronic lymphocytic leukemia (CLL). However, there is an ongoing transformation in CLL management with a plethora of new or soon-to-be-available promising experimental treatment options with remarkable activities, favorable toxicity profiles, and convenient administration schedules. Conventional ...
متن کاملTreatment of fludarabine-refractory chronic lymphocytic leukemia.
The development of resistance to purine analogs defines a poor-risk subset of patients with chronic lymphocytic leukemia (CLL). Although in recent years chemoimmunotherapeutic combinations such as fludarabine, cyclophosphamide, and rituximab have induced response rates of 95% in previously untreated patients and increased the rates of failure-free survival, CLL remains incurable for many patien...
متن کامل